Cargando…

Add-on-LUCAS2™-Reanimation am NEF Innsbruck

STUDY GOAL: The study goals were to analyze the course and compare it with patients who were only resuscitated manually as well as to record the influencing factors in patients in whom the mechanical chest compression aid LUCAS2™ was used as an add-on treatment at the NEF Innsbruck. MATERIAL AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwaiger, D., Zanvettor, A., Neumayr, A., Baubin, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525372/
https://www.ncbi.nlm.nih.gov/pubmed/35389080
http://dx.doi.org/10.1007/s00101-022-01112-z
_version_ 1784800691534954496
author Schwaiger, D.
Zanvettor, A.
Neumayr, A.
Baubin, M.
author_facet Schwaiger, D.
Zanvettor, A.
Neumayr, A.
Baubin, M.
author_sort Schwaiger, D.
collection PubMed
description STUDY GOAL: The study goals were to analyze the course and compare it with patients who were only resuscitated manually as well as to record the influencing factors in patients in whom the mechanical chest compression aid LUCAS2™ was used as an add-on treatment at the NEF Innsbruck. MATERIAL AND METHODOLOGY: Retrospective history data analysis of patients in the study period from 01.01.2014 to 31.12.2019 of the NEF Innsbruck from the German Resuscitation Register (GRR), in which LUCAS2™ was used as an add-on treatment according to an emergency doctor’s order. RESULT: A total of 123 add-on LUCAS2™ applications (18.8%) were performed in 653 resuscitations. Of all patients 16.2% survived the first 30 days. By using add-on-LUCAS2(TM) application 7.3% (9/123) of all add-on LUCAS2(TM) resuscitations and 1.4% (n = 9) of all CPR survived. Cardiac arrest was observed in 8/9 add-on LUCAS2™ 30-day survivors and bystander CPR was performed and 8/9 showed ventricular fibrillation as the primary rhythm. Compared to manual CPR alone, add-on LUCAS2™ resuscitation was used highly significantly (p < 0.001) more frequently in younger, male patients, in public, in shockable initial rhythms and during transport, and significantly more frequently in observed cardiac arrest (p < 0.05). The 30-day mortality with additive lysis treatment was 100%. DISCUSSION: By using add-on LUCAS2™ CPR a percentage increase in survival rate can be achieved and thus appears advantageous (1.4% in our study). This means that high-quality CPR can be carried out on patients with favorable prognostic factors, even with technically complex rescue operations (turntable ladder, staircase, transport in an ambulance) and thus transport can be made possible; however, there is a higher admission rate under CPR and thus the treatment target decision is shifted to the shock room.
format Online
Article
Text
id pubmed-9525372
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-95253722022-10-02 Add-on-LUCAS2™-Reanimation am NEF Innsbruck Schwaiger, D. Zanvettor, A. Neumayr, A. Baubin, M. Anaesthesiologie Originalien STUDY GOAL: The study goals were to analyze the course and compare it with patients who were only resuscitated manually as well as to record the influencing factors in patients in whom the mechanical chest compression aid LUCAS2™ was used as an add-on treatment at the NEF Innsbruck. MATERIAL AND METHODOLOGY: Retrospective history data analysis of patients in the study period from 01.01.2014 to 31.12.2019 of the NEF Innsbruck from the German Resuscitation Register (GRR), in which LUCAS2™ was used as an add-on treatment according to an emergency doctor’s order. RESULT: A total of 123 add-on LUCAS2™ applications (18.8%) were performed in 653 resuscitations. Of all patients 16.2% survived the first 30 days. By using add-on-LUCAS2(TM) application 7.3% (9/123) of all add-on LUCAS2(TM) resuscitations and 1.4% (n = 9) of all CPR survived. Cardiac arrest was observed in 8/9 add-on LUCAS2™ 30-day survivors and bystander CPR was performed and 8/9 showed ventricular fibrillation as the primary rhythm. Compared to manual CPR alone, add-on LUCAS2™ resuscitation was used highly significantly (p < 0.001) more frequently in younger, male patients, in public, in shockable initial rhythms and during transport, and significantly more frequently in observed cardiac arrest (p < 0.05). The 30-day mortality with additive lysis treatment was 100%. DISCUSSION: By using add-on LUCAS2™ CPR a percentage increase in survival rate can be achieved and thus appears advantageous (1.4% in our study). This means that high-quality CPR can be carried out on patients with favorable prognostic factors, even with technically complex rescue operations (turntable ladder, staircase, transport in an ambulance) and thus transport can be made possible; however, there is a higher admission rate under CPR and thus the treatment target decision is shifted to the shock room. Springer Medizin 2022-04-07 2022 /pmc/articles/PMC9525372/ /pubmed/35389080 http://dx.doi.org/10.1007/s00101-022-01112-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Originalien
Schwaiger, D.
Zanvettor, A.
Neumayr, A.
Baubin, M.
Add-on-LUCAS2™-Reanimation am NEF Innsbruck
title Add-on-LUCAS2™-Reanimation am NEF Innsbruck
title_full Add-on-LUCAS2™-Reanimation am NEF Innsbruck
title_fullStr Add-on-LUCAS2™-Reanimation am NEF Innsbruck
title_full_unstemmed Add-on-LUCAS2™-Reanimation am NEF Innsbruck
title_short Add-on-LUCAS2™-Reanimation am NEF Innsbruck
title_sort add-on-lucas2™-reanimation am nef innsbruck
topic Originalien
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525372/
https://www.ncbi.nlm.nih.gov/pubmed/35389080
http://dx.doi.org/10.1007/s00101-022-01112-z
work_keys_str_mv AT schwaigerd addonlucas2reanimationamnefinnsbruck
AT zanvettora addonlucas2reanimationamnefinnsbruck
AT neumayra addonlucas2reanimationamnefinnsbruck
AT baubinm addonlucas2reanimationamnefinnsbruck